On Friday, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) was 11.25% up from the session before settling in for the closing price of $3.91. A 52-week range for FDMT has been $2.23 – $28.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -64.94% over the last five years. When this article was written, the company’s average yearly earnings per share was at -19.97%. With a float of $41.55 million, this company’s outstanding shares have now reached $46.32 million.
The firm has a total of 227 workers. Let’s measure their productivity. In terms of profitability, gross margin is 17811.11%, operating margin of -2259177.78%, and the pretax margin is -1960433.33%.
4D Molecular Therapeutics Inc (FDMT) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward 4D Molecular Therapeutics Inc stocks. The insider ownership of 4D Molecular Therapeutics Inc is 10.31%, while institutional ownership is 88.02%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.94 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -19.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.31% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
You can see what 4D Molecular Therapeutics Inc (FDMT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 12.36. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10075.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.37, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -3.87 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Analysing the last 5-days average volume posted by the [4D Molecular Therapeutics Inc, FDMT], we can find that recorded value of 0.35 million was lower than the volume posted last year of 0.7 million. As of the previous 9 days, the stock’s Stochastic %D was 86.02%. Additionally, its Average True Range was 0.28.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 45.30%, which indicates a significant decrease from 98.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.18% in the past 14 days, which was lower than the 89.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.31, while its 200-day Moving Average is $6.79. Now, the first resistance to watch is $4.49. This is followed by the second major resistance level at $4.62. The third major resistance level sits at $4.88. If the price goes on to break the first support level at $4.09, it is likely to go to the next support level at $3.83. Now, if the price goes above the second support level, the third support stands at $3.69.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
There are 46,325K outstanding shares of the company, which has a market capitalization of 201.51 million. As of now, sales total 40 K while income totals -160,870 K. Its latest quarter income was 10 K while its last quarter net income were -47,970 K.
